Literature DB >> 18225996

The impact of disease recurrence on graft survival following liver transplantation: a single centre experience.

Ian A Rowe1, Kerry Webb, Bridget K Gunson, Naimish Mehta, Sayeed Haque, James Neuberger.   

Abstract

Many diseases that cause liver failure may recur after transplantation. A retrospective analysis of the rate and cause of graft loss of 1840 consecutive adults receiving a primary liver transplant between 1982 and 2004 was performed to evaluate the rate of graft loss from disease recurrence. The risk of graft loss from recurrent disease was greatest, when compared to primary biliary cirrhosis (PBC), in those transplanted for hepatitis C virus (HCV) [hazard ratio (HR) 11.6; 95% confidence interval (CI) 5.1-26.6], primary sclerosing cholangitis (PSC) (HR 6.0; 95% CI 2.5-14.2) and autoimmune hepatitis (AIH) (HR 4.1; 95% CI 1.3-12.6). The overall risk of graft loss was also significantly greater in HCV (HR 2.1 vs. PBC; 95% CI 1.5-3.0), PSC (HR 1.6 vs. PBC; 95% CI 1.2-2.3) and AIH (HR 1.6; 95% CI 1.0-2.4) than in PBC. There was no statistically significant difference in the risk of graft loss because of recurrent disease, when compared with PBC, for patients transplanted for alcohol related liver disease, nonalcoholic steatohepatitis and fulminant hepatic failure. Disease recurrence is a significant cause of graft loss particularly in HCV, PSC and AIH. Recurrent disease, in part, explains the increased overall risk of graft loss in these groups.

Entities:  

Mesh:

Year:  2008        PMID: 18225996     DOI: 10.1111/j.1432-2277.2007.00628.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  27 in total

1.  Impact of donor and recipient race on survival after hepatitis C-related liver transplantation.

Authors:  Jennifer E Layden; Scott J Cotler; Shellee A Grim; Michael J Fischer; Michael R Lucey; Nina M Clark
Journal:  Transplantation       Date:  2012-02-27       Impact factor: 4.939

Review 2.  Long-term survival after liver transplantation for alcoholic liver disease.

Authors:  Paula Iruzubieta; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 3.  Primary biliary cirrhosis and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara
Journal:  Intractable Rare Dis Res       Date:  2012-05

Review 4.  Autoimmune hepatitis.

Authors:  Farhad Sahebjam; John M Vierling
Journal:  Front Med       Date:  2015-03-06       Impact factor: 4.592

5.  Nonalcoholic Steatohepatitis: The Second Leading Indication for Liver Transplantation in the USA.

Authors:  Marcio F Chedid
Journal:  Dig Dis Sci       Date:  2017-10       Impact factor: 3.199

6.  Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases--an analysis of the UNOS database.

Authors:  Randeep Kashyap; Saman Safadjou; Rui Chen; Parvez Mantry; Rajeev Sharma; Vrishali Patil; Manoj Maloo; Charlotte Ryan; Carlos Marroquin; Christopher Barry; Gopal Ramaraju; Benedict Maliakkal; Mark Orloff
Journal:  J Gastrointest Surg       Date:  2010-07-09       Impact factor: 3.452

Review 7.  Recurrence of autoimmune liver diseases after liver transplantation.

Authors:  Nabiha Faisal; Eberhard L Renner
Journal:  World J Hepatol       Date:  2015-12-18

8.  [Treatment of autoimmune liver diseases. Autoimmune hepatitis and primary sclerosing cholangitis].

Authors:  C P Strassburg; M P Manns
Journal:  Internist (Berl)       Date:  2011-12       Impact factor: 0.743

Review 9.  Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation.

Authors:  Jan Peveling-Oberhag; Stefan Zeuzem; Wolf Peter Hofmann
Journal:  Med Microbiol Immunol       Date:  2009-11-10       Impact factor: 3.402

10.  Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.

Authors:  Alice Tung Wan Song; Rodolphe Sobesky; Carmen Vinaixa; Jérôme Dumortier; Sylvie Radenne; François Durand; Yvon Calmus; Géraldine Rousseau; Marianne Latournerie; Cyrille Feray; Valérie Delvart; Bruno Roche; Stéphanie Haim-Boukobza; Anne-Marie Roque-Afonso; Denis Castaing; Edson Abdala; Luiz Augusto Carneiro D'Albuquerque; Jean-Charles Duclos-Vallée; Marina Berenguer; Didier Samuel
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.